AUTHORS
Zainab Shahid, MBBS, Meighan Palazzo2, Sarah Samorodnitsky, PhD3, Silvia Escribano Serrat, MD4, Sigrun Einarsdottir, MD, PhD5, Marina Gomez-Llobell, MD6, Roni Shouval Jr, MD, PhD7, Parastoo B. Dahi, MD8, Alexander P. Boardman, MD9, Lorenzo Falchi, MD10, Mark Blaine Geyer, MD11, Sergio Giralt, MD12, Hamza Hashmi, M.D.13, Heather J. Landau, MD14, Alexander M. Lesokhin, MD15, Richard J. Lin, MD, PhD16, Jennifer Kimberly Lue, M.D.17, Sham Mailankody, MBBS18, Maria Lia Palomba, MD19, Sridevi Rajeeve, MD20, Gilles Salles I, MD, PhD21, Craig Sauter, MD22, Michael Scordo, MD23, Saad Z. Usmani, MD24, Genovefa Papanicolaou25, Susan K. Seo26, Jae H Park, MD27, Miguel-Angel Perales, MD28, Mini Kamboj29, Gunjan L. Shah, MD, MS30
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, United States
22 Memorial Sloan Kettering Cancer Center, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, United States
24 Memorial Sloan Kettering Cancer Center, New York, United States
25 Memorial Sloan Kettering Cancer Center, New York, United States
26 Memorial Sloan Kettering Cancer Center, New York, United States
27 Memorial Sloan Kettering Cancer Center, New York, United States
28 Memorial Sloan Kettering Cancer Center, New York, United States
29 Memorial Sloan Kettering Cancer Center, New York, United States
30 Memorial Sloan Kettering Cancer Center, New York, United States
ABSTRACT
Background: Recipients of CD19 and BCMA CAR T-cell Therapy develop prolonged B cell aplasia and hypogammaglobulinemia, leading to an extended at-risk period of vaccine preventable infections. Vaccine schedule post CAR T-cell therapy is often adapted from Hemopoietic Cellular therapy (HCT) literature, and optimal schedule of vaccine initiation and necessary doses remains poorly defined. Based on our published work, we hypothesized that the vaccine schema post CAR T- cell therapy should be different from HCT recipients. In September 2024, our center adopted a serology guided vaccination strategy. Herein we describe the uptake and immunogenicity under this strategy focusing on seroprotection after one dose and the incremental gain from a second dose.
Methods: We conducted a single-center, IRB-approved retrospective analysis of CD19 or BCMA-directed CAR T therapy recipients between September 2024 and June 2026. Patients were eligible for vaccination at 6 months, if they had not started new line of therapy and were off immunoglobulin replacement therapy. Pre-vaccine titers were drawn, and patients received one dose of vaccine against 6 antigens (PCV20, Hib, Tdap, polio, hepatitis A and B). Post vaccine titers were drawn 1-3 months after the first dose. A second dose was triggered if patients were not seroprotected and had partial response to 1st dose (second dose was delayed until immune recovery if no response to 1st dose, defined at B cell > 25cell/µL, CD4 >200/µL, IgG > 400 mg/L). Using pre-specified institutional protective thresholds and fold-rise criteria result was categorized as responder, non-responder (NR), immune but not evaluable (INE; seroprotected at baseline) or missing (M) after each vaccine. Outcomes were reported as a proportion of evaluable patients.
Results: Among 377 CAR T- cell therapy recipients between September 2024 to June 2026, 19 patients received at least one vaccine under this strategy. Among these 19, median age was 67 years (IQR 64-73) and 13 (68%) were men, 12 (63%) had myeloma (BCMA CAR T recipients) and 7 (37%) had lymphoid malignancy (CD19 CAR T recipients). Median time to first vaccination was 7.8 months (IQR 6.7–8.8).
Several patients exhibited pre-vaccine titers that already met protective thresholds, including 8/14 (53%) for Hepatitis B, 7/16 (44%) for varicella, 5/13 (38%) for polio, 4/18 (22%) for Haemophilus influenzae type b (Hib), 14/16 (88%) for tetanus, 9/16 (56%) for diphtheria, and 3/16 (19%) for pertussis. Hepatitis A serology was available in 3 patients and were seroprotected at baseline.
First dose seroprotection varied markedly: tetanus 12/13 (92%, NR=1), diphtheria 11/14 (79%, NR=3, INE=0), polio 8/13 (62%, NR= 0, INE=5), pertussis 6/14 (43%, NR =8 , INE= 0, M=2), HiB 6/16 (38%, NR=8, INE=4), pneumococcus 3/15 (20%, NR=12, INE=0), hepatitis B 1/14 (7.1%, NR=5, INE=8, M=1) and varicella 1/14( 7%, NR= 6,INE =7, M=2).
Number of patients given additional doses included 2 for tetanus, 2 for diphtheria, 1 for polio, 2 pertussis, 2 for HiB, 2 for pneumococcal, 1 for hepatitis B and 2 for varicella. Incremental gain from a second dose was minimal. Overall seroprotection among vaccines recipients was tetanus 13/14 (93%), diphtheria 12/15 (80%), polio 8/13 (62%), pertussis 7/15 (47%), HiB 6/17 (35%), pneumococcus 4/16 (25%), hepatitis B 1/14 (7.1%) and varicella 2/14 (14%). Second doses were rare, each added at least one responder for diphtheria, pertussis, pneumococcus, and varicella antigen but none for hepatitis B.
Fourteen of 19 patients (74%) responded to at least one antigen. In exploratory univariate analysis neither age at infusion (OR 1.01, 95% CI 0.89-1.12; p=0.9) nor CAR T target (CD19 vs BCMA: OR 3.00, 95% CI 0.33-67.2; p=0.4) predicted response in univariate analysis: additional analysis including immune parameters is underway.
Conclusion: Loss of immunity against vaccine preventable pathogens remains variable post CAR T-cell therapy. A serology-based strategy enabled a personalized approach to revaccination, decreasing dose burden. Our data suggest that a single revaccination dose may suffice for tetanus, diphtheria and polio if serological assessment is not available. However, this apporach is inadequate for pneumococcus, pertussis, hepatitis B, and varicella, where revaccination strategy should include careful timing of additional doses to align with immune reconstitution. Small sample size and incomplete serology data limit inference, this analysis will be updated.
DISCLOSURES
Zainab Shahid, MBBS: Merck & Co. - Research Funding; CSL Behring - Research Funding; Invivyd - Consultancy (Includes expert testimony)